Advocacy Group Demands FDA Clarity for Rare Diseases

Coalition Urges FDA Reform Amid Investment Downturn

A coalition representing nearly 100 rare disease patient groups, biotech executives, and investors has formally urged the Trump administration to restore regulatory clarity at the FDA's Center for Biologics Evaluation and Research (CBER). The call to action comes as a survey reveals 84% of biotech investors have reduced or halted investments in the sector due to recent regulatory uncertainty.

Overview of the Situation

The Rare Disease Advocacy, Biotechnology, and Investor Coalition sent a letter to President Donald Trump and other key health officials. The letter was prompted by the upcoming departure of Dr. Vinay Prasad, the current head of CBER, and concerns over the center's increasing inflexibility in overseeing rare disease clinical trials.

The coalition argues that this uncertainty has made it significantly harder for biotech companies to raise capital over the past year. The group is advocating for a new CBER leader who understands the unique challenges of developing treatments for rare diseases and prioritizes patient and physician perspectives.

Economic and Market Impact

The regulatory environment has had a direct negative impact on the biotech industry. Data shows a sharp increase in application rejections, with CBER rejecting about half of its late-stage programs in 2025. This contrasts sharply with just one rejection out of 20 programs over the prior two years.

This trend continued into the first quarter of 2026, where CBER approved only one orphan drug while issuing two Complete Response Letters (CRLs). The difficulty in securing approvals and capital has created a challenging environment for innovation and investment in therapies for rare conditions.

Summary

The coalition's primary demand is for stable and predictable leadership at the FDA's CBER to restore investor confidence and support the development of crucial rare disease therapies. The market will be closely watching the administration's choice for the next CBER head, as it will signal the future direction of biologic and gene therapy regulation.

FAQ

Q: What is the main issue raised by the coalition?
A: The coalition is concerned about a lack of regulatory clarity and flexibility at the FDA's CBER, which is discouraging investment in rare disease treatments.

Q: How has this uncertainty affected the biotech industry?
A: According to a survey, 84% of biotech investors have reduced or exited rare disease investments, and companies are finding it harder to raise capital.

Q: What is a Complete Response Letter (CRL)?
A: A CRL is issued by the FDA when it determines that it will not approve a drug application in its current form.

Source: Investing.com